antipyrine has been researched along with Lymphoma, Non-Hodgkin in 2 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It should be taken into account when dosing drugs which are metabolized as markers of the liver metabolic efficiency like phenazone and sulphadimidine." | 2.68 | [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms]. ( Kotlarek-Haus, S; Milejski, P; Orzechowska-Juzwenko, K; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wiela-Hojeńska, A, 1997) |
| " The mean phenazone half-life (t0." | 1.27 | Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ( Kotlarek-Haus, S; Orzechowska-Juzwenko, K; Plamieniak, B; Wiela, A; Wolowiec, D, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wiela-Hojeńska, A | 1 |
| Milejski, P | 1 |
| Orzechowska-Juzwenko, K | 2 |
| Usnarska-Zubkiewicz, L | 1 |
| Urbaniak-Kujda, D | 1 |
| Kotlarek-Haus, S | 2 |
| Wiela, A | 1 |
| Plamieniak, B | 1 |
| Wolowiec, D | 1 |
1 trial available for antipyrine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
[Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Topics: Acetylation; Adolescent; Adult; Aged; Antipyrine; Disease Susceptibility; Female; Hodgkin Disease; H | 1997 |
1 other study available for antipyrine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Female; Hodgkin Disease; Humans; | 1988 |